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Abstract Cancer has been considered as temporal and
spatial aberrations of normal development in tissues.
Similarities between mammary embryonic development
and cell transformation suggest that the underlying pro-
cesses required for mammary gland development are also
those perturbed during various stages of mammary
tumorigenesis and breast cancer (BC) development. The
master regulators of embryonic development Cripto-1,
Notch/CSL, and Wnt/b-catenin play key roles in modu-
lating mammary gland morphogenesis and cell fate speci-
fication in the embryo through fetal mammary stem cells
(fMaSC) and in the adult organism particularly within the
adult mammary stem cells (aMaSC), which determine
mammary progenitor cell lineages that generate the basal/
myoepithelial and luminal compartments of the adult
mammary gland. Together with recognized transcription
factors and embryonic stem cell markers, these embryonic
regulatory molecules can be inappropriately augmented
during tumorigenesis to support the tumor-initiating cell
(TIC)/cancer stem cell (CSC) compartment, and the effects
of their deregulation may contribute for the etiology of BC,
in particular the most aggressive subtype of BC, triple-
negative breast cancer (TNBC). This in depth review will
present evidence of the involvement of Cripto-1, Notch/
CSL, and Wnt/b-catenin in the normal mammary gland
morphogenesis and tumorigenesis, from fMaSC/aMaSC
regulation to TIC generation and maintenance in TNBC.
Specific therapies for treating TNBC by targeting these
embryonic pathways in TICs will be further discussed,
providing new opportunities to destroy not only the bulk
tumor, but also TICs that initiate and promote the metastatic
spread and recurrence of this aggressive subtype of BC.
Keywords Cripto-1  Notch/CSL  Wnt/b-catenin 
fMaSC/aMaSC  TIC/CSC  TNBC
Introduction
The mammary gland is a very dynamic organ, which starts
to develop in the embryo by signals exchanged between the
ventral epithelial cells and underlying mesenchymal cells
[1]. However, most of mammary gland developmental
program completes postnatally, and the gland will become
entirely functional only in adult life. During mouse
embryonic development, specification of mammary
epithelial cell fate occurs at mid-gestation as cells aggre-
gate to form a bilateral milk line followed by the appear-
ance of two sets of distinct placodes, one on each side of
the embryo. The subsequent formation and ingrowth of
mammary placode buds is followed by branching of the
nascent mammary duct [2, 3]. A rudimentary ductal tree
then forms during the latter stages of embryonic develop-
ment via progressive elongation, canalization, and
branching of the anlage (primitive mammary organ), which
continues to invade the fat pad precursor. Ductal structures
persist in a relatively quiescent state following birth until
puberty. During mouse puberty, which occurs at 4–6 weeks
of age, mammary epithelial cells undergo variable amounts
of terminal end bud (TEB) formation, duct elongation,
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dichotomous, and lateral side branching. In the female
human breast, terminal duct lobular unit formation and
stromal expansion also occur during puberty [2]. At preg-
nancy, in both species, the mammary gland undergoes
extensive side branching and alveolar development occurs
in preparation for lactation. Upon cessation of lactation and
during involution, the gland regresses to a previous state,
which resembles the virgin or nulliparous gland. Epithelial
cell plasticity of the developing mammary gland is influ-
enced by ovarian (e.g., estrogen, progesterone) and pitu-
itary (e.g., prolactin) hormones, as well as locally derived
growth factors that are hormonally regulated and can be
expressed either in the epithelial cells, stromal cells, adi-
pocytes, mast cells, or macrophages that surround the
TEBs [4]. The fundamental processes required for the
inductive events in mammary bud development are also
those that are perturbed during various stages of mammary
tumorigenesis and breast cancer (BC) development [5].
Embryonic signaling pathways that regulate mammary cell
fate specification and patterning in the embryo through
fetal mammary stem cells (fMaSC), and in the adult
organism through adult mammary stem cells (aMaSC), can
also determine mammary progenitor cell lineages, which
will generate the basal/myoepithelial and luminal com-
partments of the mammary gland (Fig. 1). The regulatory
molecules that modulate these processes can be inappro-
priately augmented during tumorigenesis to support the
tumor-initiating cells (TICs)/cancer stem cells (CSCs)
compartment [5]. In this review, we will discuss the roles
of the embryonic development master regulators Cripto-1,
Notch/CSL, and Wnt/b-catenin in mediating mammary
gland morphogenesis and cell fate specification, and the
effects of their deregulation in the etiology of BC, in par-
ticular the most aggressive subtype of BC, triple-negative
breast cancer (TNBC). Lastly, we will outline existing
clinical applications using Cripto-1, Notch/CSL, and Wnt/
b-catenin signaling molecules as therapeutic targets in
TNBC.
Cripto-1, Notch/CSL, and Wnt/b-catenin signaling
in Mammary Gland Development
The epidermal growth factor (EGF)-Cripto-1-FRL-1-
Cryptic (CFC) family encompasses several members
identified in deuterostomes, especially in vertebrates [6].
Human Cripto-1 is the founding member of this family and
primarily functions during embryogenesis as a co-receptor
for the transforming growth factor beta (TGF-b) family of
ligands Nodal and growth and differentiation factors 1 and
3 (GDF-1, -3) in a canonical pathway, leading to the
activation of the Activin type I (Alk4,7)/Activin type II
(ActRII) receptor complex that subsequently triggers
phosphorylation of Smad-2/Smad-3, and the activation of
this Smad-dependent intracellular signaling pathway
mediated by Smad-4 [7] (Fig. 2). Cripto-1 is anchored to
the cell membrane by a glycosylphosphatidylinositol (GPI)
lipid moiety within lipid rafts [8] and can also function in a
Smad-independent non-canonical pathway, acting as a
ligand for the GPI-anchored heparan sulfate proteoglycan
Glypican-1, which is also tethered to the plasma membrane
within lipid raft microdomains, to activate the tyrosine-
protein kinase (c-Src)/mitogen-activated protein kinase
(MAPK) and phosphatidylinositol 3 kinase (PI3 K)/protein
kinase B (AKT) signaling pathways that regulate cell
proliferation, motility, and survival [7] (Fig. 2). Both
canonical and non-canonical Cripto-1 signaling pathways
can be significantly amplified by GRP78/BIP (78 kDa
glucose-egulated protein/binding immunoglobulin protein),
which belongs to the endoplasmic reticulum stress response
pathway [9] (Fig. 2). During embryonic mammary gland
development, Cripto-1 is expressed in the mesenchymal
cells surrounding the mammary placodes but not in the
epithelial placodes, similar to the expression pattern of
Msx2, Lef1, and b-catenin in the canonical Wnt/b-catenin
signaling pathway [4]. In fact, Cripto-1 is a direct target
gene in the Wnt/b-catenin pathway [10]. Postnatally,
Cripto-1 can be detected at low levels in the ductal
epithelial cells of the virgin mouse mammary gland and its
expression significantly increases during early to mid-
pregnancy, and early lactation, being also detected in
human breast milk [11]. In the virgin mouse mammary
gland, Cripto-1 is localized in the luminal epithelial cells
and cap cells of the advancing TEBs and within the
branching ducts, and contributes to the induction of
epithelial plasticity, epithelial-to-mesenchymal transition
(EMT), and ductal invasion into the mammary fat pad of
the developing gland [4]. In the initial stages of pregnancy,
Cripto-1 is upregulated by progesterone and can directly
regulate progesterone receptor (PR) expression in luminal
progenitor cells of the mouse mammary gland, triggering
side branching, and alveologenesis induced by the receptor
activator of nuclear factor kappa B (NF-jB)-ligand
(RANKL) signaling pathway [12] (Fig. 1).
Mammals possess four Notch membrane-tethered
receptors (Notch1-4) and five ligands (Jagged 1, 2 and
Delta-like, Dll 1, 3, and 4) [13]. Notch receptors undergo
proteolytic maturation by a furin-like protein convertase
(S1 cleavage) in the Golgi/Endoplasmic Reticulum, and
Notch signaling turns on upon ligand-receptor interaction
in a short-range intercellular communication system
between neighboring cells, which induces sequential pro-
teolytic cleavages of the four mature Notch receptors. The
second cleavage (S2) occurs in the extracellular domain
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(ECD) and is mediated by metalloproteases of the A dis-
integrin and metalloproteinase (ADAM) family. The last
cleavage (S3) happens within the transmembrane domain
and is mediated by a gamma secretase presenilin complex,
allowing the release and translocation of the intracellular
domain of Notch (NICD) into the nucleus where it
associates with a transcription complex containing a CSL
(CBF-1 in human and RBPJ-j in mouse) transcription
regulator. This interaction converts the multiprotein CSL
co-repressor complex into a transcription co-activator
complex resulting in increased expression of Notch target




























































































































Fig. 1 Hypothetical hierarchical organization of normal mammary
epithelial cells and their potential relationship with defined human
breast cancer molecular subtypes. Isolation of cells from mouse and
human mammary tissues supports this schematic hierarchical orga-
nization of the mammary gland development. Multipotent fetal
mammary stem cells (fMaSC) give rise to adult mammary stem cells
(aMaSC). Long-lived aMaSCs in turn generate transitional common
progenitor cells (CommProg) that can commit to either basal/
myoepithelial (BasalProg) or luminal progenitor (LumProg) cells.
BasalProg cells develop mature basal cells (MatureBasal), and
LumProg cells produce either ductal progenitor (DuctalProg) or
alveolar progenitor cells (AlveoProg), which in turn generate mature
luminal cells (MatureLum) in the form of mature ductal or alveolar
cells, respectively. Disruption in the homeostasis of any of these
cells—from the most primitive/undifferentiated (fMaSC/aMaSC) to
the most differentiated cells (ductal and alveolar cells)—may lead to
the development of mammary/breast tumors. The more undifferen-
tiated, greater the potential of proliferating and self-renewing for
multiple generations, and therefore accumulating deleterious genetic
and/or epigenetic alterations that can persist over the lifespan of an
individual. These cells may possibly become putative cancer stem
cells (CSC) or tumor-initiating cells (TIC), implicated in the etiology
of the distinct molecular subtypes of breast cancer (BC). For
mammary/breast tumor development, reactivation of embryonic stem
cell (ES) markers (shown in purple), certain transcriptional factors
(TF) (shown in red or green) and crucial developmental signaling
pathways (shown in blue), such as Cripto-1, Notch/CSL and Wnt/b-
catenin, result in increased proliferation and restoration of self-
renewal capacity of mammary epithelial cells, as well as enable the
initiation of a de-differentiation program. A schematic illustration of
recognized regulatory cross-talk occurring between master regulators
of mammary gland development and tumorigenesis discussed in this
review is depicted in figure. Some examples of commonly mutated
and/or amplified genes other than BRCA1/2 in the different subtypes
of BC include TP53, PTEN, AKT, RB1, PIK3CA, TBX3, FOXA1,
CDH1, CBFB, MAP3K1, NF1, KRAS, KIT, MET, FGFR1/2, BRAF,
EGFR, RUNX1, MLL3, and MAP2K4 [40], but they are not
represented in figure. TNBC triple-negative breast cancer; ER
estrogen receptor; PR progesterone receptor; interm intermediary; hi
high; lo low; mut mutation
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Canonical CSL-mediated Notch signaling is crucial in the
regulation of mammary cell communication during
embryogenesis, stem cell self-renewal, cell lineage com-
mitment, cellular proliferation, differentiation, and apop-
tosis in the mouse and human mammary gland [14, 15].
Notch expression is temporally and spatially regulated in
mammary epithelial cells during mouse mammary gland
development. In the postnatal mammary gland, Notch1-3
mRNA expression levels increase from 5 weeks of age






































































































Fig. 2 Signaling cascades of Cripto-1, Notch/CSL, and Wnt/b-
catenin. The transduction of Cripto-1 signaling (shown in blue)
occurs through both the canonical signaling pathway mediated by
Smad2/3 with Smad4 following Nodal/GDF-1, -3 activation of the
Activin type I receptor (Alk4,7)/Activin type II (ActRII) receptor
complex and the non-canonical pathway resulting in MAPK activa-
tion by GRP78 or Glypicans through Src. Therapeutic interventions
(shown in red) for this pathway include antisense oligos to inhibit
Cripto-1 expression, small molecule antagonists, and monoclonal
antibodies (mAbs) against the EGF domain of Cripto-1 to inhibit the
non-canonical pathway, Alantolactone, small molecule antagonists,
mAbs against the CFC domain of Cripto-1 and the Cripto-1 ligand
Nodal to inhibit the canonical Smad-mediated signaling, and a
cytotoxin-conjugated non-neutralizing mAb against the amino termi-
nus of Cripto-1 to directly kill target cells. Notch/CSL activation
(shown in yellow) occurs when a Jagged (Jag) or Delta-like (Dll)
ligand bound to an adjacent cell binds a Notch receptor on the target
cell facilitating cleavage by ADAM proteases extracellularly fol-
lowed by the gamma secretase complex intracellularly, releasing the
Notch intracellular domain (NICD) which translocates to the nucleus
to transactivate transcription through CSL. Therapeutic strategies
against Notch include Notch antisense oligonucleotides, mAbs
against Notch ligands, mAbs against Notch receptors, and gamma
secretase inhibitors. The canonical Wnt/b-catenin pathway (in green)
involves the binding of a Wnt ligand to a Frizzled receptor (Fzd) with
the aid of a Lrp co-receptor. Stimulation of Fzd results in the
activation of Disheveled (Dvl) which in turn inhibits the b-catenin
destruction complex, glycogen synthase kinase 3 b (GSK-3b)/
axin/casein kinase 1 a (Ck1a)/adenomatous polyposis coli (Apc),
allowing b-catenin to translocate to the nucleus to initiate Tcf/Lef
transactivation in the context of Pygo, BCL9, and CBP. The non-
canonical Wnt pathway (in green) involves the activation of Fzd and
Dvl leading to the subsequent activation of the c-Jun N-terminal
kinase (JNK) and phospholipase C (PLC) triggering gene activation
independently of b-catenin. The Wnt family can also activate the
ROR family of receptor tyrosine kinases to potentiate JNK activation.
Therapeutic strategies have involved mAbs against various members
of the Frizzled family, a Frizzled 8-Fc-conjugated decoy receptor, a
radiolabeled anti-Frizzled-10 mAb, and small molecule antagonists
against Porcupine and b-catenin/CBP binding
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displaying the lowest levels during early involution (apop-
totic stage) and late involution (quiescent mammary gland)
[16]. Notably, Notch3 mRNA expression is the most
abundant at all the stages of mammary gland development,
while Notch4 expression is almost undetectable [16].
Transgenic mice expressing a constitutively active Notch4
(Int3) under the control of the mouse mammary tumor virus
(MMTV) promoter showed restriction of cell fate selection
in the mammary epithelial cells, exhibiting arrested mam-
mary gland development with reduced ductal growth and
secretory lobule development, resulting in loss of lactation
[17]. Eventually, these mice develop poorly differentiated
adenocarcinomas [17]. However, mammary glands of mice
harboring the Int3 transgene driven by the whey acidic
protein (WAP) promoter, where activity is restricted to the
secretory mammary epithelial cells, only showed disruption
in lobular differentiation, but not in ductal growth/extension
[18]. Interestingly, mammary ducts of transgenic virgin
WAP-Int3 females were able to fill the fat pad completely
and seemed morphologically normal, but during gestation at
late pregnancy, lobular development was severely impaired
with almost no alveolar outgrowth, which failed to exhibit
milk protein production in full-term pregnant females.
Female mice fail to lactate due to this severe impairment in
alveolar development. Importantly, mammary tumorigene-
sis occurred in all breeding and non-breeding WAP-Int3
females, although with a higher latency period in nulli-
parous females [18].
The Wnt/b-catenin signaling pathway includes 19 Wnt
ligands, 10 Frizzled (Fzd) receptors, and two co-receptors—
low-density lipoprotein receptor-related protein (Lrp) 5 and
6. Binding of secreted Wnt ligands to Fzd receptors and
Lrp5/6 co-receptors at the cell surface induces a complex
series of interactions to activate the canonicalWnt/b-catenin
signaling. Fzd, upon binding to a subset of Wnt ligands,
recruits the mediator disheveled (Dvl) and interferes with
the constitutively active b-catenin multiprotein destruction
complex, composed of Axin/conducting, adenomatous
polyposis coli (Apc), and casein kinase 1 a (Ck1a), which
enhance glycogen synthase kinase 3 beta (GSK3b) phos-
phorylation and results in inactivation of GSK3b function.
Normally, GSK3b phosphorylates b-catenin, marking it for
destruction through an ubiquitin-mediated degradation
pathway [13]. However, if GSK3b becomes phosphorylated
by Ck1a, its ability to phosphorylate b-catenin will be
thereby blocked, and then non-phosphorylated b-catenin
will accumulate in the cytoplasm, consequently enhancing
its translocation to the nucleus, where it can activate target
genes, such as Cripto-1, Cyclin-D1, and Lgr5, upon inter-
action with T cell factor (Tcf)/Lymphoid enhancer factor
(Lef) DNA binding proteins [10, 19, 20] (Fig. 2). Wnt/b-
catenin signaling is essential for initiating formation of the
mammary milk line in the embryo and further becomes
restricted to mesenchymal cells surrounding the mammary
epithelial placodes that invaginate to form flask-shaped buds
[15]. The activation of b-catenin signaling in the embryonic
mammary mesenchymal compartment can promote stem
cell amplification and branching morphogenesis [21]. In the
adult mammary gland, Wnt/b-catenin signaling works in a
cell-specific manner, inducing ductal morphogenesis in
basal epithelial cells in a paracrine manner, and promoting
alveologenesis in hormone receptor-negative luminal
epithelial cells [22]. Remarkably, Wnt4, which is inducible
by progesterone, regulates an important hormonal phase in
the luminal progenitor mammary epithelial cell compart-
ment, activating progesterone-induced side branching and
RANKL effectors during lobulo-alveolar development in a
paracrine fashion [23] (Fig. 1). In fact, mammary glands
lacking the expression of Wnt4 exhibited delayed alveolo-
genesis during pregnancy [24]. On the other hand, mammary
epithelial cells overexpressing Wnt4 and Wnt1 develop
hyperplastic outgrowths, and with Wnt1 subsequent mam-
mary tumors [25, 26]. Interestingly, ectopic expression of
Wnt3 in mammary epithelial cells expressing Cripto-1 sig-
nificantly enhanced cell transformation induced by Cripto-1
[10]. Conversely, Cripto-1 can enhance Wnt/b-catenin sig-
naling activation by directly binding to the Lpr5 and Lpr6
co-receptors and facilitating Wnt3 binding to these co-re-
ceptors [10]. In addition to the potential role in inducing
mammary tumorigenesis, a positive feedback-signaling loop
may exist between these two pathways that might be also
essential in regulating mammary alveologenesis, consider-
ing that both Cripto-1 [12] and Wnt/b-catenin [23] are
essential for RANKL-induced alveologenesis. A compre-
hensive summary of the expression and function of Wnt/b-
catenin signaling effectors during mammary gland devel-
opment can be found in Alexander and colleagues [25].
Cripto-1, Notch/CSL, and Wnt/b-catenin signaling
in fetal mammary stem cells (fMaSC) and adult
mammary stem cells (aMaSC)
fMaSC and aMaSC
The observation that the mammary gland exhibits plasticity
and a unique regenerative capacity through multiple cycles
of pregnancy, lactation, and involution, accompanied by
dynamic changes in proliferation, differentiation, cell
death, and tissue remodeling, suggests that there exist
subpopulations of renewable stem and/or progenitor cells
underlying these processes. A population of epithelial cells
exists in the fetal mammary anlage of the embryo, which
has a self-renewal capacity and the ability to generate
daughter cells that can differentiate into distinct progenitor
cell lineages that will form all of the cell types that are
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present in the mature mammary gland [5, 27] (Fig. 1). The
cell specification process is initiated by the expansion of
fMaSCs, which constitute the earliest MaSC population
[27]. fMaSCs are bipotent (CK8?/CK14?) and can be
enriched using the cell surface marker profile CD24hi/
CD49fhi [27]. Although differing from the CD29hi/CD24?
aMaSC marker signature, fMaSCs are also able to recon-
stitute fully differentiated mammary outgrowths with
functional and morphologically normal structures upon
transplantation into the cleared mammary fat pad, with a
repopulation capacity about four-fold higher as compared
to the repopulation frequency of the aMaSCs [27]. More-
over, fMaSCs present significantly higher clonogenic
capability as compared to aMaSCs [28]. However, aMaSCs
are likely to derive from their embryonic counterpart
fMaSCs, and along with their potential of extensive self-
renewing for multiple generations, both populations are
thought to harbor inherent tumorigenic potential as subse-
quent mammary development proceeds and continues
postnatally. Kenney and colleagues showed that aMaSCs
can survive up to 6–7 divisions and may exist either as
long-lived (non-dividing) cells or as proliferating-differ-
entiating cells (transitional units) [29]. A lineage tracing
study reported that aMaSCs are unipotent [30]. Conversely,
a more recent study provides strong evidences for the
existence of a bipotent aMaSC population, which gives
raise to both basal and luminal cells, and coordinates ductal
homeostasis and remodeling of the adult mammary gland
[31]. Upon asymmetrical division, aMaSC subpopulations
can organize the mammary epithelium into two distinct
amplifying cell lineages that are usually defined by their
clonogenic activity in vitro, which are either basal/my-
oepithelial or luminal progenitors. Basal/myoepithelial cell
lineages express p63 [32], smooth muscle actin and basal
cytokeratins (CK5 and CK14) and are localized in a basal
position adjacent to the basement membrane, presenting
contractile properties [1]. The luminal lineage is governed
by the expression of steroid hormone receptors and luminal
cytokeratin proteins (CK8, CK18, and CK19), as well as b3
integrin (CD61), which subdivides the total luminal pop-
ulation into committed luminal progenitors (CD29lo/
CD24?/CD61?) and mature luminal cells (CD29lo/CD24?/
CD61-) [33]. The mature luminal cells are represented by
the ductal sub lineage, which will form the luminal struc-
tures, and the alveolar sub lineage, which will generate the
milk-producing alveolar units from alveolar progenitors
arising from the luminal progenitor compartment [1].
Additionally, several key transcriptional regulators are
involved in the determination of the aMaSC population and
also in the initiation and maintenance of luminal progenitor
cells (Fig. 1). For instance, the Sox9 transcription factor
directly regulates the Slug promoter [34] and together they
modulate aMaSC activity [35]. In fact, primary mammary
epithelial cells containing Sox9 and Slug knocked-down
exhibited a significantly reduced aMaSC-enriched basal
subpopulation [35]. Conversely, their co-expression in dif-
ferentiated luminal cells is sufficient to convert these cells
into aMaSCs with long-term reconstituting ability in vivo
[35] (Fig. 1). Interestingly, overexpression of Slug alone in
luminal progenitor cells can convert these cells into a basal
state [35]. In addition, the lack of Slug expression in the
mouse mammary gland delays mammary gland develop-
ment during puberty, and epithelial cells isolated from these
glands overexpress the estrogen receptor (ER) and the
transcription factor Gata3, and loose their potential to
generate secondary mammospheres [36]. Gata3 is a neces-
sary master regulator for enhancing and maintaining cell
fate specification of luminal progenitor cells into mature
ductal cells during puberty and induces the differentiation
of luminal progenitor cells into mature alveolar cells during
pregnancy [33] (Fig. 1). Notably, ectopic expression of
Gata3 in the aMaSC subpopulation induces milk protein
expression in the absence of any hormonal lactogenic
stimuli [33]. Elf5 encodes a member of the ETS family of
transcription factors and is upregulated in fMaSCs, as well
as regulates alveolar cell differentiation of mammary cells
during pregnancy [37]. Importantly, Elf5 directly represses
the transcription of Slug, impairing a basal-fate program,
and the lack of Elf5 during pregnancy and lactation acti-
vates an EMT-like phenotype [38]. Besides differentiation,
Elf5 is also essential for morphogenesis of mature alveolar
cells, with no influence on ductal cells [39]. Moreover, Elf5
might prevent the de-differentiation program of luminal
progenitor cells into a more primitive state, since its loss
increases the repopulating capacity of aMaSCs [38] and
activates Notch/CSL signaling pathway [39] (Fig. 1).
The long-term survival of aMaSCs could allow more
time for cumulative genetic lesions in multiple genes (e.g.,
Tp53, PTEN) to be acquired as DNA damage/mutations
may increase throughout postnatal development [40].
Progenitor cells adversely affected by these genetic alter-
ations and also epigenetic modifications, such as altered
methylation of genes could then persist over the lifespan of
an individual and effectively create a quiescent subpopu-
lation of cells that may well harbor potentially deleterious
mutations, instabilities, and genomic translocations. These
cells could then become activated by altered extrinsic
signaling pathways and convert these quiescent cells into
putative TICs, fostering unlimited, or extended self-re-
newal capacity since human breast tumors may take many
years to arise [5]. Importantly, during tumorigenesis,
luminal progenitor cells can acquire the ability to inter-
convert between phenotypes, which could potentially
explain the cellular heterogeneity within the different types
of BC. The luminal progenitor compartment can become
very metaplastic upon oncogenic stress, wherein luminal
216 Breast Cancer Res Treat (2016) 156:211–226
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progenitor cells in particular can produce basal-like tumor
cells [41] especially after excessive Notch/CSL signaling
activation [42] and loss and/or mutation of the tumor-
suppressor gene BRCA1 [43, 44] (Fig. 1).
Cripto-1, Notch/CSL, and Wnt/b-catenin regulate
fMaSC and aMaSC
Cripto-1 is a direct downstream target gene of the
pluripotency embryonic stem (ES) cell master regulators
Nanog and Oct-4 [45], and reciprocally, in cooperation
with Nodal and Activin, Cripto-1 is essential in maintain-
ing Nanog and Oct-4 expression through a Smad-depen-
dent signaling pathway [46]. Nanog, Oct4 and Sox2 are
present in aMaSCs and luminal progenitor cells population,
and their expression decreases when these cells start to
differentiate [47, 48] (Fig. 1). Likewise, Spike and col-
leagues (2014) found that Cripto-1 could promote
pluripotency of fMaSCs and aMaSCs ex vivo and enhance
their potential to reconstitute the mammary gland through
an aMaSCs/progenitor cell subpopulation (Fig. 1). In
addition, they demonstrated that the cell surface receptor
GRP78/BIP is required for fMaSC and aMaSC activity and
for Cripto-1 responsiveness [49]. Together, Cripto-1 and
GRP78/BIP seem to play a developmentally conserved role
in regulating the fMaSC and aMaSC phenotypes.
Notch/CSL signaling can also regulate aMaSCs to pro-
mote self-renewal and enhance lineage-specific commit-
ment of basal/myoepithelial progenitor cells, as well as to
increase their proliferation rate, with no apparent effects on
fully differentiated mammary epithelial cells [50] (Fig. 1).
Stimulation of the canonical Notch pathway also promotes
branching morphogenesis in three-dimensional matrigel
cultures, which can be completely inhibited by a Notch4
blocking antibody or a gamma secretase inhibitor, that
prevents S3 cleavage and processing of the Notch receptors
[50]. Notch3 activation directly stimulates commitment of
luminal progenitor cells to a luminal cell fate commitment
[51]. In fact, Notch3 is expressed in a highly clonogenic
luminal progenitor population that gives rise to ductal lin-
eages. These cells are able to survive multiple successive
pregnancies, since Notch3 possibly restricts their prolifer-
ation and clonal expansion [52]. Notch1 was also found to
commit aMaSC expansion to the luminal cell fate, being
preferentially activated in the ductal luminal epithelium
in vivo [53], and inappropriate Notch1 activation promotes
self-renewal and transformation of luminal progenitor cells
[53]. Recently, Rodilla and colleagues showed that Notch1
is expressed in the fMaSC population, which possesses a
very restricted lineage potential to exclusively generate an
ER- luminal lineage postnatally, and alveolar progenitors
that express Notch1 and expand during pregnancy, surviv-
ing multiple successive involutions [54].
The Wnt/b-catenin signaling component Axin2 has been
studied in the mouse mammary gland, where Axin2-ex-
pressing mammary cells were found to reside exclusively in
the aMaSC-enriched subpopulation [55]. Remarkably, van
Amerongen and colleagues showed that Axin2-responsive
mammary cells resident in the basal compartment of pre-
pubescent mammary gland are unipotent and retain long-
term proliferative potential. In fact, Axin2-positive cells
transplanted into cleared mouse mammary fat pads after
puberty generated only basal cells [56]. However, these
Axin2 basal-restricted cells switched to bipotent stem cells
during pregnancy, as they gave rise to both luminal and
basal cells present in the alveolar structures [56]. Lgr5 is
another Wnt/b-catenin member that marks a rare subpop-
ulation of cells within the basal compartment and induces
mammary reconstitution activity in vivo [57]. Interestingly,
a single Lgr5-expressing cell can efficiently generate an
entire functional mammary outgrowth [57]. During early
postnatal development, a very small fraction of Lgr5-posi-
tive mammary cells was able to switch from luminal-
committed cells to a basal-fate phenotype [58] (Fig. 1).
Also, Wnt3a can clonally expand aMaSCs for multiple
generations and enhance their ability to generate functional
mammary glands following in vivo transplantation [55].
Additionally, luminal cells with decreased levels of Wnt4
inhibited the self-renewing capacity of aMaSCs, as shown
by the enrichment of differentiation genes and a significant
reduction of proliferation-associated genes [53]. The Wnt/
b-catenin co-receptor Lrp5 also plays crucial roles in
maintaining aMaSC activity in the mammary gland [59].
Importantly, Cripto-1 binds to Lrp5 and facilitates Wnt3a
binding to Lrp5, enhancing Wnt/b-catenin signaling
through cytoplasmic stabilization of b-catenin and elevated
b-catenin/Tcf transcriptional activation [10]. Likewise,
Wnt3a increases migration, invasion, and anchorage-inde-
pendent growth of Cripto-1-expressing normal mouse
mammary epithelial cells [10]. TheWnt/b-catenin signaling
co-activator Pygopus (Pygo) 2 was shown to suppress
luminal differentiation of the aMaSC-enriched population
by coordinating the activity of Wnt/b-catenin and Notch
signaling pathways [60]. Interestingly, in parous mice, the
expression of Notch/CSL pathway members seems to be
increased in the aMaSC-enriched population in comparison
to the expression of Wnt/b-catenin target genes [61].
Cripto-1, Notch/CSL, and Wnt/b-catenin signaling
pathways are enhanced in breast cancer (BC)
Distinct subtypes of BC may originate from different cells
of origin [62]. As previously discussed, abnormal regula-
tion of the multifaceted mammary epithelial hierarchy may
further give rise to different BC molecular subtypes,
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possibly explaining the heterogeneous nature of human BC
[63]. There are currently 5 defined molecular subtypes of
BC: claudin-low/metaplastic, basal-like, HER-2-positive
(HER-2?), luminal A, and luminal B [64] (Fig. 1). Basal-
like and claudin-low breast cancers are often referred as
TNBC, since the tumors are typically negative for ER, PR,
and HER-2 (ER-/PR-/HER-2-) and are usually associated
with a poor prognosis and decreased survival rate [65].
While Cripto-1 is required for mammary gland mor-
phogenesis and hematopoietic stem cell renewal, unregu-
lated expression of Cripto-1 is found in a number of
different types of human cancers, including breast, pros-
tate, cervix, colon, bladder, lung, and melanoma [7].
Additionally, soluble Cripto-1 levels are elevated in the
plasma obtained from colon, lung, glioblastoma, and BC
patients, what suggests that Cripto-1 levels in human
plasma or serum may have potential clinical diagnostic and
prognostic significance [7]. A genome-wide association
study for Cripto-1 serum levels performed in an isolated
human population, aiming to identify genetic variants
associated with the levels of circulating Cripto-1 protein in
the serum, confirmed its fundamental role in embryonic
development and cancer [66]. Moreover, GRP78/BIP is
expressed on the surface of tumor cells [67] where it
preferentially binds to GPI-anchored proteins [68], and it
has been shown that Cripto-1/GRP78/BIP complex
increases tumor growth [69]. Cripto-1 is also involved in
the reprogramming of differentiated BC cells into TICs
through the induction of an EMT program [4]. Recently, it
has been shown that the transcription factor Snail, which is
a mediator of EMT, can regulate the expression of Cripto-1
[70] and vice versa [71] (Fig. 1), controlling responses
such as cell motility, transformation, and differentiation.
Additionally, Cripto-1 has a strong angiogenic activity in
cultured endothelial cells and is involved in regulating new
blood vessel formation in developing breast tumors [7].
Furthermore, Cripto-1 may be involved in the immune
escape of malignant cells and immunosuppression of tumor
cells by enhancing macrophage phagocytic activity and
upregulating the production of anti- and pro-inflammatory
cytokines such as tumor necrosis factor alpha (TNF-a) and
interleukin 6 (IL-6), through the NF-jB signaling pathway
[72]. Moreover, Cripto-1 modulates Notch/CSL and Wnt/
b-catenin signaling pathways, which are also involved in
the etiology of BCs, as next discussed. Cripto-1 can
function as a chaperone for Notch receptors in the Golgi/
Endoplasmic Reticulum compartment by enhancing S1
cleavage of Notch receptors by recruiting furin-like pro-
teases and sensitizing S1 cleavage and ligand-induced
activation of Notch/CSL signaling [73]. Additionally,
Cripto-1 acts as an auxiliary positive modulator by facili-
tating the binding of Wnt3 to the Lrp5 and Lrp6 Wnt co-
receptors, thereby enhancing Wnt/b-catenin signaling [10].
Constitutive activation of Notch signaling is present in
approximately 50 % of BCs. Recently, a pathway and
network analysis of gene expression and immunohisto-
chemical profiling of BC has revealed that Notch signaling
is critical for maintaining ER?/PR?/HER-2- breast tumors
and for cell cycle regulation in ER?/PR?/HER-2? breast
tumors [74]. Interestingly, deregulation of Notch signaling
appears to occur early in pre-invasive ductal carcinomas.
Elevated expression levels of Notch1, Notch4, and Hes1
can be detected in ductal carcinoma in situ (DCIS) as
compared to normal mammary tissue [75]. Several muta-
tions have been observed in the Notch1/2 receptors in
TNBC [76]. Furthermore, exome sequencing continues to
reveal mutations in Notch signaling components within
BC, among them multiple gain-of-function and frequent
loss or inactivation of the negative regulator Numb [75].
Notably, Notch signaling is implicated in regulating tumor-
stroma interactions, metastasis and chemotherapeutic
resistance in BC. Both Notch1 and Notch4 receptors are
overexpressed in basal-like TNBC and vascular endothelial
cells with a subcellular localization different from that in
hormone-positive luminal BC [77]. In addition, Notch1
directly induces the vascular endothelial growth factor
receptor 3 (VEGFR-3) in blood vessel endothelial cells,
which regulates vascular development and subsequently
lymphangiogenesis [77]. Meta-analysis of microarray data
from over 4000 BC patients has revealed that the elevated
Notch/CSL pathway activity is independently associated
with an increased rate of disease recurrence [78]. Likewise,
in mice, Notch signaling remains activated in a subset of
dormant residual tumor cells that persist following HER-2
down-regulation and accelerates tumor recurrence [78].
Additionally, a Notch1-Slug axis was shown to be vital for
the Jagged1-induced promotion of EMT, migration, and
invasion of BC [79].
Canonical Wnt/b-catenin signaling can be constitutively
activated in different types of cancer, such as colorectal
carcinoma, by a variety of mechanisms including mutations
in b-catenin, Apc, and Axin [75]. In general, these muta-
tions enable b-catenin to escape destruction and drive
oncogenic Wnt/b-catenin signaling. However, mutations in
Apc or b-catenin generally occur in low frequency in BC.
Despite the lack of direct gene mutations, elevated levels of
b-catenin expression have been detected in approximately
60 % of BCs, and additionally in many cases, aberrant
hypermethylation of the Apc gene promoter has also been
reported, as well as upregulation of Wnt/b-catenin signal-
ing pathway target genes such as Lef1 and Axin2, espe-
cially in the TICs population of BC [75]. Aristizabal-
Pachon and collaborators recently described genetic alter-
ations in Axin2, which were associated with a higher risk
of developing BC, and also an aberration in the b-catenin
destruction complex expression profile associated with BC.
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Moreover, the same study reported for the first time
expression of the b-catenin destruction complex in circu-
lating tumor cells from peripheral blood of BC patients [80].
Secretion of Wnt/b-catenin ligands into the niche microen-
vironment may have a non-cell autonomous/paracrine effect
on cells at the invasive edge of breast tumors by increasing
tumor cell proliferation, EMT, and subsequent tumor cell
invasion. Analysis of human cancer datasets confirms that
elevated Wnt/b-catenin gene expression in BC correlates
with expression of genes with an EMT signature, such as
Vimentin, Snail, and Twist [81]. Several novel molecular
mechanisms that might contribute to aberrantWnt/b-catenin
activation and progression in BC have been described.
Among them, BCL9, a nuclear co-factor that binds b-catenin
and Pygo, modulates canonical Wnt/b-catenin signaling by
promoting b-catenin-mediated transcription [82]. The
TCGA breast cancer database indicates that BCL9 is sig-
nificantly amplified in basal-like subtypes of BC. Further-
more BCL9 expressionwas also detected in ER-/PR-/HER-
2?DCIS lesions [82]. Also, the Pitx2 isoform 1 transcription
factor, which is a target gene in the Nodal/Cripto-1 andWnt/
b-catenin signaling pathways, is known to contribute to the
invasion of BC cells. Pitx2 was found in the bone marrow of
BC patients and was significantly associated with metastatic
BC development [83].
Cripto-1, Notch/CSL, and Wnt/b-catenin signaling
pathways regulate tumor-initiating cells (TIC)
and contribute to the etiology of triple-negative
breast cancer (TNBC)
Similar to fMaSC, aMaSC, and luminal progenitor cells, a
small subpopulation of TICs or CSCs exists, which share
characteristics with the above normal mammary stem cells
and possess self-renewal and partial differentiation capac-
ity in human breast tumors [1]. TICs are proposed to
recapitulate the original phenotype of BC, to enhance
tumor relapse and contribute to chemotherapy and radio-
therapy resistance and/or facilitate metastasis [84]. Inter-
estingly, the invasion and metastasis program of TNBC is
intrinsically related to an aMaSC population signature,
which predisposes this subpopulation of BC cells to facil-
itate subsequent metastasis [85]. However, molecular pro-
filing studies have revealed that the more primitive aMaSC/
basal signature is most closely aligned with metaplastic
claudin-low subtype of BC [65, 86], suggesting that a very
aggressive aMaSC subpopulation may give rise to claudin-
low BCs (Fig. 1). Conversely, the expression profile of
basal-like BC is not concordant with the aMaSC-enriched
subset, but with the expression signature of a luminal
progenitor population [87]. In fact, Pfefferle and colleagues
showed that 94 % of basal-like tumors exhibited a luminal
progenitor profile, while claudin-low subtype represented
the highest percentage of primitive aMaSCs (18 %) [88],
indicating indeed that they may arise from a more primitive
aMaSC population, and most probably due to aberrations in
Wnt/b-catenin signaling [62] (Fig. 1). Intriguingly, 59 %
of the claudin-low tumors were also classified as presenting
luminal progenitor characteristics [88].
The processes of somatic cell reprogramming, TICs
establishment and metastatic colonization are dependent on
transitions between EMT and its reverse process mes-
enchymal-epithelial transition (MET) that occurs in the
colonized end organs following metastasis, such as in the
lung and brain [89]. Similarities between embryonic devel-
opment and cell transformation during oncogenesis have
been previously reported [90]. In particular, EMT performs
an essential role during embryonic development in gastru-
lation [4]. However, if EMT is inappropriately activated in
BC cells, it can induce the formation of migratory mes-
enchymal cells that possess stem cell-like phenotypes, TICs
properties, and an invasive capacity with a high metastatic
potential [90, 91]. These similarities have led to the identi-
fication of common ES cell markers, such as Nanog, Oct4,
and Sox2, as also expressed in mammary tumors [92–94],
significantly increasing the potential of TICs cells to form
mammospheres and promote metastatic invasion [47].
Additionally, a Nanog/Oct4/Sox2 expression signature was
directly associated with high-grade TNBC basal-like sub-
type and with poor clinical outcome [95] (Fig. 1). Notably,
the embryonic signaling pathways addressed in this review,
Cripto-1, Notch/CSL and Wnt/b-catenin, when inappropri-
ately reactivated in populations of aMaSC and/or progenitor
cells, may generate TICs, which can potentially drive
mammary cell transformation, tumor progression, and
invasion in adult mammary tissues (Fig. 1).
Cripto-1 is also one of the stemness genes that have been
shown to generate induced pluripotent stem cells (iPSC) and
is essential in maintaining normal ES cells and initiating
EMT, as well as being expressed in TIC subpopulations and
contributing to early cancer progression [84, 96–98]. In fact,
Cripto-1 expression is significantly enhanced in basal-like
and HER-2? breast tumors (Fig. 1), which derive from a
common luminal progenitor population, suggesting that
Cripto-1 might be important in the etiology or progression of
BC subpopulations [99]. In this context, Cripto-1 has been
suggested as a novel therapeutic target in a Notch4-driven
spontaneous model of TNBC [100]. Cripto-1 promoter
activity was detected in spindle-like areas exhibiting EMT
phenotype of mouse primary tumors that resemble human
TNBC, but not in lung metastasis. Additionally, Cripto-1
knockout resulted in a significant inhibition of primary
tumor growth and a pronounced reduction in the number and
size of pulmonary metastases, suggesting that Cripto-1 may
contribute to mammary oncogenesis in TNBC [100].
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Elevated expression of the Notch3 receptor has been
correlated to TNBC [52]. Recently, a novel Notch reporter
system revealed that all Notch receptors (1-4) are able to
mediate the regulation of BC TICs, and specifically Notch4
expression was correlated with poor patient survival in a
TCGA breast tumor dataset analysis (cBioPortal) [101].
Indeed, both Notch1 and Notch4 are expressed in aMaSCs
and TICs, but in particular, Notch4 has been shown to
maintain the human TICs population [14, 102]. Treatment
with the gamma secretase inhibitor RO4929097 decreased
primary tumor growth and significantly reduced the num-
ber of metastatic lung nodules in an animal model that
resembles human TNBC and overexpresses Notch4 [100].
Additionally, the activity of TICs and Notch4 was proven
to govern both de novo and acquired tamoxifen resistance,
and Notch4 inhibition reduced TICs activity in patient-
derived xenograft (PDX) tumors with acquired anti-estro-
gen resistance [103]. Therefore, the combination of endo-
crine therapy and Notch4-targeting therapy might
overcome anti-estrogen resistance in human BC.
Wnt/b-catenin directs cell fate determination at various
stages of development and is implicated in EMT during
early embryogenesis, such as in gastrulation. In adults,
Wnt/b-catenin signaling has a key role in the regulation of
tissue stem self-renewal, particularly in the intestinal
crypts, hair follicles, bone growth plates, bone marrow,
mammary gland morphogenesis, and in mouse and human
mammary tumorigenesis [15, 89]. Accumulating evidence
indicates a critical role of Wnt/b-catenin signaling in the
functioning of TICs. A recent report has shown that
blockade of Wnt/b-catenin signaling suppressed BC
metastasis by inhibiting TICs-like phenotype [104].
Moreover, another study showed that pan-PI3K inhibitors,
a treatment option for TNBC, activated canonical Wnt/b-
catenin signaling through stimulation of Wnt ligand
secretion leading to treatment resistance in TNBC cells
[105]. This resistance was decreased through combined
treatment with pan-PI3 K and Wnt inhibitors [105]. These
findings indicate that Wnt/b-catenin pathway activation
conferred resistance in TNBC. Collectively, these findings
suggest a crucial role and potentially functional cross-talk
of Cripto-1, Wnt/b-catenin, and Notch/CSL in the regula-
tion of TICs, EMT, and resistance to therapy in TNBC.
Cripto-1, Notch/CSL, and Wnt/b-catenin signaling
members as new prognostic tools and therapeutic
targets for tumor-initiating cells (TIC) in triple-
negative breast cancer (TNBC)
Due to the reactivation of several developmental signaling
pathways in the initiation and progression of breast tumors
in concordance with their respective roles in TICs and
TNBC, they may well be appropriate candidates as prog-
nostic markers and therapeutic targets. The prognostic
value of all three developmental signaling pathways has
been explored to varying degrees in several cancers. The
determination of which pathways are activated in TICs or
progenitor subpopulations could lead to patient-specific
therapy that targets TICs involved in tumor initiation,
metastasis, and chemotherapeutic and radiation resistance.
Since Cripto-1 can promote mammary tumorigenesis, EMT
[4], and can be also present in a TICs population [84], its
expression might provide be a significant prognostic mar-
ker. In fact, a previous study from our laboratory found
Cripto-1 expression at least 10-fold higher in the plasma of
breast and colon cancer patients compared to healthy
control subjects [106]. Likewise, Cripto-1 is expressed at
significant levels in high-grade breast tumors and correlates
with an overall decrease in patient survival [7, 107]. Sim-
ilar findings have been found in gastric cancer patients with
a concurrent down-regulation of E-cadherin, signifying an
increase of metastatic disease [108]. Recently, our labora-
tory has found the expression of anti-Cripto-1 autoanti-
bodies in patients with glioblastoma [109]. The production
of autoantibodies against a target such as Cripto-1 could
provide a predictive marker, as well as a potential thera-
peutic strategy as some autoantibodies act as agonistic
ligands [109]. To date, therapies directed against Cripto-1
have mostly been non-clinical and employed a variety of
approaches including antisense oligonucleotides, human-
ized mouse, or rat monoclonal antibodies, either conju-
gated or not to drugs, and a naturally occurring small
natural product, Alantolactone [7] (Fig. 2). Recently, a
study examining a panel of small molecules from the NCI
diversity library found 4 compounds that were able to
inhibit canonical Cripto-1 signaling through Smad2 and
varying degrees of efficacy in inhibiting non-canonical
signaling through the c-Src/AKT/MAPK pathway [109]
(Fig. 2). Furthermore, a phase I clinical trial of refractory
solid tumors using a humanized monoclonal antibody
against Cripto-1 conjugated with the cytotoxin maytansi-
noid complex DM4 (BIIB015) was completed and showed
no toxicity with preliminary partial positive responses
[110, 111] (Fig. 2). In addition, when BIIB015 was used in
combination with paclitaxel for treating human xenograft
mouse mammary tumors from the TNBC cell line MDA-
MB-231, this dual treatment protocol conferred a robust
activity by inhibiting tumor growth by 90 % in comparison
to treatment with either of the agents alone, suggesting that
BIIB015 could enhance the efficacy of chemotherapeutic
agents against TNBC [111]. Most recently, Cripto-1 DNA
vaccination generated protective response elicited by
CD8?T cells against lung metastasis in a highly metastatic
melanoma mouse model by targeting a small subpopulation
of melanoma stem cells expressing Cripto-1 [112]. This
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DNA vaccine was also highly effective against aggressive
TICs (listed as an abstract), which makes it very attractive
to be tested in a TNBC model. Further clinical testing will
be necessary to elucidate the true value of these approaches
and other drug and/or antibody combinations.
As with Cripto-1, members of the Notch/CSL pathway
have been assessed for potential prognostic value. High
expression levels of Notch ligands and receptors have been
associated with poor patient survival [75]. The mRNA
expression of Notch1 receptor was correlated with increased
mortality in PR- tumors, while augmented expression of
Notch2, 3, and 4mRNAcorrelatedwith better overall survival
for all BC patients [113]. Another study, examining the
expression of the Notch family members by in situ
hybridization revealed that the expression of Notch1, Notch3,
and Jagged1 predicted higher mortality and increased patient
relapse [114]. Although the sample size for this study was
small, tumors expressing high levels of Notch1, Notch3, or
Jagged1 were phenotypically classified as TNBC. To this
point, patients with tumors co-expressing high levels of both
Notch1 and Jagged1 had a stronger correlation with mortality
[114]. To date, there have been a number of approaches
approved for clinical trials to target theNotch/CSLpathway in
multiple tumor types. For example, there have been a number
of clinical trials using gamma secretase inhibitors either alone
or in combination with chemotherapeutic agents to treat solid
tumors as wells as leukemias [115] (Fig. 2). Monoclonal
antibodies against various Notch signaling components are
also in clinical trial, such as antibodies directed against
Notch1, Notch2/3, and DII4 [115] (Fig. 2). Other approaches
such as siRNAs that are directed against Notch1, Notch3, or
CBF-1 showed that the CD44? subset ofMCF-7 breast tumor
cells underwent apoptosis and were further sensitized to
radiotherapy in vitro [116].
Due to the pivotal role of the Wnt/b-catenin pathway in
TNBC, the possibility exists to use the expression of pro-
teins of this signaling pathway as prognostic indicators in
TNBC, as well as therapeutic targets. Interestingly, the
expression of Wnt1 is higher in BC tissues as compared to
normal breast tissues, but there is no difference observed in
the clinical grade of the tumors suggesting that Wnt1 might
be an early marker of tumorigenesis, but not a significant
prognostic marker [117]. High expression of the tyrosine
kinase-like orphan receptor 1 (ROR1), loss of the Wnt
signaling antagonist Frizzled-related protein 1 (SFRP1) in
early breast tumors, and nuclear localization of b-catenin
all correlate with increased metastasis and reduced over-
all survival in BC patients in general with higher correla-
tions observed in basal-like and claudin-low breast tumors
[118–120]. Interestingly, a study of ovarian cancer detected
autoantibodies against a number of proteins, including
b-catenin [121]. In contrast, another study found that the
expression of Apc, a negative regulator of b-catenin
activity, is increased in grade-3 BC tumor tissue while
showing a decrease in the normal surrounding breast tissue.
In this study, b-catenin was found in the cytoplasm of tumor
cells but did not localize to the nucleus and its expression
decreased as the tumor grade increased [117]. Overall, the
expression levels of certain Wnt/b-catenin family members
correlate with a more aggressive tumor type and therefore a
poor outcome. Current clinical strategies for targeting the
Wnt/b-catenin pathway include small molecule antagonists
against CBP/b-catenin binding and Porcupine (LGK-974),
the latter being involved in Wnt secretion [115] (Fig. 2).
Therapies targeting the Fzd proteins include a monoclonal
antibody directed against Fzd-1/2/5/7/8 (Vantictumab), a
radiolabelled monoclonal antibody for Fzd-10, and a Fzd-8-
Fc decoy fusion protein (Fig. 2). In particular, Vantictumab
in combination with paclitaxel and LGK-974 are currently in
Phase I clinical trials for luminal BC and TNBC, respec-
tively [115] (Fig. 2). Other experimental approaches to tar-
get the Wnt/b-catenin pathway that have been explored, but
are beyond the scope of this review can be found in Anastas
and Zheng and colleagues [122, 123]. In summary, these
three families of signaling pathways are potentially attrac-
tive targets for specific therapies designed to attack breast
tumors, in particular TNBC. Furthermore, the use of com-
binatorial cocktails of chemotherapeutic agents with these
signaling inhibitors in conjunction with radiotherapy pro-
vides the opportunity to destroy not only the bulk tumor, but
also TICs that initiate and promote the metastatic spread and
recurrence of TNBC.
Conclusion
In this comprehensive review, we present clear evidence of
the involvement of Cripto-1, Notch/CSL, and Wnt/b-cate-
nin signaling pathways in the fetal and adult mammary
gland development through the modulation of fMaSC,
aMaSC, and mammary progenitor cells. We also discuss
the contribution of these signaling pathways in the gener-
ation of TICs and their involvement in the development,
maintenance, and resistance to therapy of TNBC, and
lastly, we provide information on new promising possi-
bilities for the treatment of this aggressive subtype of BC.
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